Abstract

CLC Number:

R994.11

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2017/V14/I6/369

[1] 许叔之.中华临床药物学[M].北京:人民出版社,2003: 579.
[2]　侯俏珍,何丽雅,黄晓燕,等. 水合氯醛不良反应2例[J]. 中国临床研究,2013,26(5):507.
[3]　Ashley L, Armitage G. Failure Mode and Effects Analysis: an Empirical Comparison of Failure Mode Scoring Procedures[J]. J Patient Saf, 2010,6(4):210-215.
[4]　Lee J, Han H, Ock M,et al. Impact of a clinical decisionsupport system for high-alert medications on the prevention of prescription errors[J].Int J Med Inform,2014,83(12):929-940.
[5]　Polischuk E, Vetterly C G, Crowley K L, et al. Implementation of astandardized process for ordering and dispensing ofhigh-alert emergency medication infusions[J]. J PediatrPharmacolTher,2012,17(2):166-172.
[6]　苏文清. 1例服用水合氯醛过量患儿的抢救及护理[J]. 首都医药, 2006,5(10): 37-38.
[7]　冯丽, 鄢爱梅, 何彩英. 1例水合氯醛灌肠致呼吸心跳骤停患儿的抢救护理[C]. 中华护理学会2009全国神经内、外科护理学术交流暨专题讲座会议论文汇编，2009:2.
[8]　李英, 刘莹, 史强, 等. 误服大剂量水合氯醛致新生儿呼吸暂停[J].药物不良反应杂志, 2015. 17(5): 395-396.
[9]　Cohen M R. Chloral hydrate overdoses implicated in deaths[J].Nursing，1993， 23(5):25.
[10]　Manias E, Williams A, Liew D,et al. Effects of patient-, environment- and medication-related factors on high-alert medication incidents[J].Int J Qual Health Care,2014,26(3):308-320.
[11]　刘艳秋. 儿科高危药品的管理[J].内蒙古医学杂志，2012,44（4）：63-64.
[12]　Catlin A.Pediatric medical errors part 2: case commentary. A source of tremendous loss[J].PediatrNurs,2004,30(4):331-335.
[13]　Abel M. Respiratory failure in a newborn infant following repeated sedation for computerized tomography[J]. KlinPadiatr, 1987,199(1):52-54.
[14]　合理用药国际网络（INRVD）中国中心组临床安全用药组，中国药理学会药源性疾病学专业委员会，中国药学会医院药学专业委员会.中国用药错误管理专家共识[J].药物不良反应杂志,2014,16(6):321-326.
[15]　Institute for Safe Medication Practices. Medication error prevention toolbox [EB/OL].(1999-06-02) [2015-01-12]. http://www.ismp.org/newsletters/acutecare/articles/19990602.asp.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.